Jagsonpal Pharmaceuticals (JAGSNPHARM) Q2 25/26 earnings summary

Executive summary

• H1 FY26 revenue grew 10.2% year-over-year to ₹1,501 million, with Q2 FY26 revenue stable at ₹745 million despite GST transition impacts.

• H1 FY26 PAT surged 39.2% year-over-year to ₹234 million, with Q2 FY26 PAT up 9.7% to ₹126 million, reflecting strong profitability momentum.

• Leadership expanded with new COO and CFO to drive growth and operational excellence.

• Unaudited financial results for the quarter and half year ended 30 September 2025 were approved by the Board on 3 November 2025.

• Maintained strong cash position of ₹1,604 million after a 125% dividend payout totaling ₹166 million.

Financial highlights

• Q2 FY26 EBITDA was ₹181 million with a margin of 24.3%; H1 FY26 EBITDA grew 8.8% year-over-year to ₹338 million, margin at 22.5%.

• Q2 FY26 gross profit at ₹472 million (63.4% margin); H1 FY26 gross profit at ₹959 million (63.9% margin).

• Q2 FY26 PAT margin improved to 16.9%; H1 FY26 PAT margin at 15.6%.

• Basic EPS for H1 FY26 was ₹3.48, compared to ₹2.52 for H1 FY25.

• Final dividend of ₹2.5 per share (125%) paid in Q2, totaling ₹166 million.

Outlook and guidance

• Management expects continued growth in H2 FY26 as GST transition challenges subside, leveraging a resilient brand portfolio.

• Targeting low double-digit (about 10%) revenue growth for FY26, with accelerated growth in subsequent years.

• GST 2.0 transition expected to support affordable healthcare and long-term market stability.